Genetic markers for ovarian cancer risk: Are we close to seeing a clinical impact?

Personalized Medicine

Volumn 9, Issue 6, 2012, Pages 565-567

  Moorman, Patricia G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

genetic variants; genome wide association studies; ovarian cancer; risk prediction

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; K RAS PROTEIN; ORAL CONTRACEPTIVE AGENT;

CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; DNA REPAIR; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HORMONE METABOLISM; HUMAN; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TRANSVAGINAL ECHOGRAPHY;

EID: 84865528636     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.58     Document Type: Review

References (18)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
2. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22), 2295-2303 (2011
3. Partridge E, Kreimer AR, Greenlee RT et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113(4), 775-782 (2009
4. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10(7), 705-713 (2001 (Pubitemid 32331579)
5. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003 (Pubitemid 36530000)
6. Antoniou AC, Cunningham AP, Peto J et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br. J. Cancer 98(8), 1457-1466 (2008 (Pubitemid 351543573)
7. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev. 20(3), 231-238 (2010
8. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: Progress to date from the Ovarian Cancer Association Consortium (OCAC)J. Intern. Med. 271(4), 366-378 (2012
9. Song H, Ramus SJ, Tyrer J et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41(9), 996-1001 (2009
10. Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42(10), 874-879 (2010
11. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J. Natl Cancer Inst. 100(14), 1037-1041 (2008 (Pubitemid 352019794)
12. Witte JS, Hoffmann TJ. Polygenic modeling of genome-wide association studies: An application to prostate and breast cancer. OMICS 15(6), 393-398 (2011
13. Machiela MJ, Chen CY, Chen C, Chanock SJ, Hunter DJ, Kraft P. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet. Epidemiol. 35(6), 506-514 (2011
14. Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009
15. Wentzensen N, Black A, Jacobs K et al. Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the prostate, lung, colorectal, and ovarian cancer screening trial. PLoS ONE 6(7), e21731 (2011
16. Ratner E, Lu L, Boeke M et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 70(16), 6509-6515 (2010
17. Keane FK, Ratner ES. The KRAS-variant genetic test as a marker of increased risk of ovarian cancer. Rev. Obstet. Gynecol. 3(3), 118-121 (2010
18. Pharoah PD, Palmieri RT, Ramus SJ et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testing. Clin. Cancer Res. 17(11), 3742-3750 (2011).